Recombinant hepatitis E vaccine (Escherichia coli) | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Brand
- Hecolin
- Company
- Xiamen Innovax Biotech; developed with Xiamen University
- Medicine type
- Vaccine
- Therapeutic area
- Prevention & diagnosis
- Indications recorded in the public source
- For susceptible individuals aged 16 years or older. Vaccination stimulates immunity against hepatitis E virus to prevent hepatitis E. Priority high-risk groups recommended in the prescribing information include livestock workers, food-service workers, students or military personnel, women of childbearing age, and travelers to endemic areas.
- Indication source and scope
- Source date(s): 2025-10-21, 2026-06-11. Manufacturer prescribing information for Mainland China.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://www.innovax.cn/listed/148.html
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.innovax.cn/wp-content/uploads/2026/09/重组戊型肝炎疫苗（大肠埃希菌）说明书-42000194-20260611-V00.pdf
Open the interactive record, public price references and discussions